Geniposide alleviates VEGF-induced angiogenesis by inhibiting VEGFR2/PKC/ERK1/2-mediated SphK1 translocation

Phytomedicine. 2022 Jun:100:154068. doi: 10.1016/j.phymed.2022.154068. Epub 2022 Mar 22.

Abstract

Background: Rheumatoid arthritis (RA) is an angiogenesis-dependent disease caused by the imbalance of pro- and anti-angiogenic factors. More effective strategies to block synovial angiogenesis in RA should be studied. Geniposide (GE), a natural product isolated from the fruit of Gardenia jasminoides Ellis (GJ), is reported to have anti-inflammatory, anti-angiogenic and other pharmacological effects. However, the underlying mechanism through which GE affects synovial angiogenesis in RA remains unclear.

Purpose: In this research, we aimed to elucidate the effect and potential mechanisms of GE on angiogenesis in RA.

Materials and methods: Synovial angiogenesis in patients with RA and a rat model of adjuvant arthritis (AA) was detected by hematoxylin and eosin (HE) staining, immunohistochemistry (IHC), and western blottiing. The biological functions of vascular endothelial cells (VECs) and sphingosine kinase 1 (SphK1) translocation were checked by CCK-8, EdU, Transwell, tube formation, co-immunoprecipitation assays, and laser scanning confocal microscopy. The effect of the SphK1 gene on angiogenesis was assessed by transfection of SphK1-siRNA in cells and mices. The effect of GE on VEGF-induced angiogenesis was measured by Matrigel plug assay in a mouse model of AA.

Results: GE effectively inhibited synovial angiogenesis and alleviated the disease process. SphK1, as a new regulatory molecule, has a potentially important relationship in regulating VEGF/VEGFR2 and S1P/S1PR1 signals. SphK1 translocation was activated via the VEGFR2/PKC/ERK1/2 pathway and was closely linked to the biological function of VECs. GE significantly reduced SphK1 translocation, thereby ameliorating the abnormal biological function of VECs. Furthermore, after transfection of SphK1 siRNA in VECs and C57BL/6 mice, silencing SphK1 caused effectively attenuation of VEGF-induced VEC biological functions and angiogenesis. In vivo, the Matrigel plug experiment indicated that GE significantly inhibited pericyte coverage, basement membrane formation, vascular permeability, and fibrinogen deposition.

Conclusions: Our findings suggest that GE inhibited VEGF-induced VEC biological functions and angiogenesis by reducing SphK1 translocation. Generally, studies have revealed that GE down-regulated VEGFR2/PKC/ERK1/2-mediated SphK1 translocation and inhibited S1P/S1PR1 signaling activation, thereby alleviating VEGF-stimulated angiogenesis. The above evidences indicated that angiogenesis inhibition may provide a new direction for RA treatment.

Keywords: Angiogenesis; Geniposide; Rheumatoid arthritis; Sphingosine kinase 1; Sphingosine-1-phosphate; Vascular endothelial growth factor.

MeSH terms

  • Animals
  • Arthritis, Experimental* / drug therapy
  • Arthritis, Rheumatoid* / drug therapy
  • Endothelial Cells / metabolism
  • Humans
  • Iridoids
  • MAP Kinase Signaling System
  • Mice
  • Mice, Inbred C57BL
  • Neovascularization, Pathologic / drug therapy
  • Neovascularization, Pathologic / metabolism
  • Phosphotransferases (Alcohol Group Acceptor)
  • RNA, Small Interfering / metabolism
  • Rats
  • Vascular Endothelial Growth Factor A / metabolism

Substances

  • Iridoids
  • RNA, Small Interfering
  • Vascular Endothelial Growth Factor A
  • geniposide
  • Phosphotransferases (Alcohol Group Acceptor)
  • sphingosine kinase